**Name of Journal:** *World Journal of Cardiology*

**Manuscript NO:** 56156

**Manuscript Type:** LETTER TO THE EDITOR

**Management of hypertension in** **COVID-19**

Antwi-Amoabeng D *et al*. Management of hypertension in COVID-19

Daniel Antwi-Amoabeng, Bryce D Beutler, Alastair E Moody, Zahara Kanji, Nageshwara Gullapalli, Christopher J Rowan

**Daniel Antwi-Amoabeng, Bryce D Beutler, Zahara Kanji, Nageshwara Gullapalli, Christopher J Rowan,** Department of Internal Medicine, Reno School of Medicine, University of Nevada, Reno, NV 89052, United States

**Alastair E Moody,** Department of Anesthesiology, University of Utah, Salt Lake City, UT 84132, United States

**Christopher J Rowan,** Renown Institute for Heart and Vascular Health, Reno, NV 89512, United States

**Author contributions:** Antwi-Amoabeng D, Beutler BD, and Moody AE wrote the letter to the editor and associated literature review; Kanji Z revised the letter; and Gullapalli N and Rowan CJ supervised the project from initiation to completion.

**Corresponding author**: Bryce D Beutler, MD, Department of Internal Medicine, Reno School of Medicine, University of Nevada, 1155 Mill Street, W-11, Reno, NV 89052, United States. bbeutler@med.unr.edu

**Received:** April 19, 2020

**Revised:** May 8, 2020

**Accepted:** May 12, 2020

**Published online:** May 26, 2020

**Abstract**

The ACE2 receptor plays a central role in severe acute respiratory syndrome coronavirus 2 host cell entry and propagation. It has therefore been postulated that angiotensin converting enzyme inhibitors and angiotensin receptor blockers may upregulate ACE2 expression and thus increase susceptibility to infection. We suggest that alternative anti-hypertensive agents should be preferred among individuals who may be exposed to this increasingly common and potentially lethal virus.

**Key words:** angiotensin converting enzyme inhibitor; angiotensin receptor blocker; carvedilol; coronavirus disease-19; COVID-19; SARS-CoV-2; verapamil

**Citaion:** Antwi-Amoabeng D, Beutler BD, Moody AE, Kanji Z, Gullapalli N, Rowan CJ. Management of hypertension in COVID-19. *World J Cardiol* 2020; 12(5): 228-230

URL: <https://www.wjgnet.com/1949-8462/full/v12/i5/228.htm>

DOI: https://dx.doi.org/10.4330/wjc.v12.i5.228

**Core tip:** The pathogenic mechanisms of severe acute respiratory syndrome coronavirus 2 remain under investigation, but data suggest that the ACE2 receptor plays a central role in infection. It is therefore possible that drugs known to increase ACE2 expression, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers, could promote viral proliferation. Data from animal studies have shown that carvedilol and verapamil attenuate inflammation in viral myocarditis. We are in agreement with the recommendation of major medical societies to maintain angiotensin converting enzyme inhibitor or angiotensin receptor blocker therapy in individuals who are already receiving treatment. However, in the age of coronavirus disease-19, alternative agents should be considered for patients with a new diagnosis of hypertension.

**TO THE EDITOR**

Coronavirus disease-19 (COVID-19) has emerged as a major cause of morbidity and mortality worldwide. As of this writing, over half a million cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have been recorded. A global arms race for a vaccine or viable therapy is currently underway. However, most experts project that development of a vaccine will take at least 18 mo[1], and an effective pharmacologic treatment has yet to be discovered. It therefore appears increasingly likely that COVID-19 will become embedded in the fabric of modern medicine for years to come.

Management of chronic illnesses in patients with COVID-19 should be considered a priority. Hypertension affects over 1.4 billion individuals worldwide[2] and has been associated with markedly increased morbidity and mortality in the setting of COVID-19[3,4]. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are among the most frequently prescribed antihypertensive agents throughout most of the developed world[5]. These drugs are safe, well-tolerated, and effective as a first-line therapy. However, emerging evidence suggests that ACEIs and ARBs may increase patient susceptibility to SARS-CoV-2 host cell entry and propagation by upregulation of the viral binding site ACE2[6-8].

There is insufficient data to recommend withdrawal of ACEIs and ARBs among individuals who have been diagnosed with COVID-19. Indeed, most major medical organizations – including the American Heart Association and European Society of Cardiology – recommend maintaining ACEI or ARB therapy in all hypertensive patients with COVID-19. However, we propose that an alternative agent should be considered in patients presenting with COVID-19 and a new diagnosis of hypertension.

Verapamil is a non-dihydropyridine calcium channel blocker that was once used for the management of hypertension. It has largely been supplanted by ACEIs, ARBs, and dihydropyridine calcium channel blockers; in the modern era, verapamil is primarily used for rate control in supraventricular tachycardia, migraine prophylaxis, and hypertension with co-morbid atrial fibrillation. We believe that this drug may be appropriate as a first-line agent for the management of hypertension in patients with COVID-19. Preliminary data from animal studies have demonstrated that verapamil has no effect on ACE2 expression. Furthermore, it has been shown to ameliorate the clinical and pathological course of viral myocarditis in murine models. Indeed, in a study of mice inoculated with encephalomyocarditis virus, investigators found that those treated with verapamil before and/or during infection exhibited markedly less cardiac inflammation and necrosis as compared to an untreated group[9]. Cardiac involvement – and, specifically, SARS-CoV-2-associated myocarditis – represents a serious and potentially fatal manifestation of COVID-19[10]. Management of hypertension with a drug that may reduce inflammation in viral myocarditis and does not pose a theoretical risk of promoting COVID-19 proliferation would appear to be a rational strategy to optimize patient outcomes.

Carvedilol, a nonselective β-adrenoreceptor antagonist with additional α1-adrenergic blocking properties, represents another promising antihypertensive agent in the setting of COVID-19. Similar to verapamil, carvedilol attenuates inflammation in murine models of acute viral myocarditis. In a study of mice infected with coxsackie B3 virus, those receiving carvedilol exhibited superior survival as compared to an untreated group and those treated with metoprolol[11]. The mechanism of action is unclear, but it has been postulated that carvedilol exerts anti-inflammatory effects via inhibition of peroxidants in the myocardium. Carvedilol also has the added benefit of reducing heart rate, which may reduce myocyte injury and ventricular remodeling in the setting of myocarditis[12].

Notably, there are demonstrable anti-inflammatory effects associated with upregulation of ACE2. Indeed, lung function improvement with ACEI or ARB treatment has been described in the setting of COVID-19[13]. However, irrespective of the purported benefits of ACEIs and ARBs, the potential of these agents to facilitate viral disease remains under investigation.

In conclusion, we believe that verapamil or carvedilol should be considered for the management of hypertension in patients at risk of COVID-19. The pathogenic mechanisms of SARS-CoV-2 remain under investigation, but data suggest that the ACE2 receptor plays a central role in infection. It is therefore theoretically possible that drugs known to increase ACE2 expression, such as ACEIs and ARBs, could promote COVID-19 proliferation. We are in agreement with the recommendation of major medical societies to maintain ACEI or ARB therapy in individuals who are already receiving treatment. However, patients with a diagnosis of hypertension who are at risk of COVID-19 would likely benefit from verapamil or carvedilol, as these agents effectively control blood pressure and may conceivably attenuate inflammation and necrosis in SARS-CoV-2 myocarditis.

**REFERENCES**

1 **Lurie N**, Saville M, Hatchett R, Halton J. Developing Covid-19 Vaccines at Pandemic Speed. *N Engl J Med* 2020 [PMID: 32227757 DOI: 10.1056/NEJMp2005630]

2 **Mills KT**, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, Chen J, He J. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. *Circulation* 2016; **134**: 441-450 [PMID: 27502908 DOI: 10.1161/CIRCULATIONAHA.115.018912]

3 **Wu C**, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med* 2020 [PMID: 32167524 DOI: 10.1001/jamainternmed.2020.0994]

4 **Zhou F**, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**: 1054-1062 [PMID: 32171076 DOI: 10.1016/S0140-6736(20)30566-3]

5 **Jarari N**, Rao N, Peela JR, Ellafi KA, Shakila S, Said AR, Nelapalli NK, Min Y, Tun KD, Jamallulail SI, Rawal AK, Ramanujam R, Yedla RN, Kandregula DK, Argi A, Peela LT. A review on prescribing patterns of antihypertensive drugs. *Clin Hypertens* 2015; **22**: 7 [PMID: 27019747 DOI: 10.1186/s40885-016-0042-0]

6 **Patel AB**, Verma A. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence? *JAMA* 2020 [PMID: 32208485 DOI: 10.1001/jama.2020.4812]

7 **Vaduganathan M**, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. *N Engl J Med* 2020; **382**: 1653-1659 [PMID: 32227760 DOI: 10.1056/NEJMsr2005760]

8 **Kuster GM**, Pfister O, Burkard T, Zhou Q, Twerenbold R, Haaf P, Widmer AF, Osswald S. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? *Eur Heart J* 2020 [PMID: 32196087 DOI: 10.1093/eurheartj/ehaa235]

9 **Dong R**, Liu P, Wee L, Butany J, Sole MJ. Verapamil ameliorates the clinical and pathological course of murine myocarditis. *J Clin Invest* 1992; **90**: 2022-2030 [PMID: 1331179 DOI: 10.1172/JCI116082]

10 **Inciardi RM**, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, Cani DS, Cerini M, Farina D, Gavazzi E, Maroldi R, Adamo M, Ammirati E, Sinagra G, Lombardi CM, Metra M. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol* 2020 [PMID: 32219357 DOI: 10.1001/jamacardio.2020.1096]

11 **Li YC**, Ge LS, Yang PL, Tang JF, Lin JF, Chen P, Guan XQ. Carvedilol treatment ameliorates acute coxsackievirus B3-induced myocarditis associated with oxidative stress reduction. *Eur J Pharmacol* 2010; **640**: 112-116 [PMID: 20457150 DOI: 10.1016/j.ejphar.2010.04.037]

12 **Guang-Yi C**, Li-Sha G, Yue-Chun L. Role of Heart Rate Reduction in the Management of Myocarditis. *Curr Pharm Des* 2018; **24**: 365-378 [PMID: 29332571 DOI: 10.2174/1381612824666180111105923]

13 **Groß S**, Jahn C, Cushman S, Bär C, Thum T. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications. *J Mol Cell Cardiol* 2020 [PMID: 32360703 DOI: 10.1016/j.yjmcc.2020.04.031]

**Footnotes**

**Conflict-of-interest statement:** The authors declare no potential conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited Manuscript

**Peer-review started:** April 19, 2020

**First decision:** May 5, 2020

**Article in press:** May 12, 2020

**Specialty type:** cardiac and cardiovascular systems

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Hasegawa h **S-Editor:** Ma YJ **L-Editor:** A **E-Editor:** Qi LL